Literature DB >> 7717983

Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.

M W Lark1, H Williams, L A Hoernner, J Weidner, J M Ayala, C F Harper, A Christen, J Olszewski, Z Konteatis, R Webber.   

Abstract

Several members of the matrix metalloproteinase family have been reported to cleave aggrecan in the interglobular domain between Asn-341 and Phe-342. An antiserum was prepared against a peptide conjugate corresponding to the C-terminal sequence of the matrix metalloproteinase-generated aggrecan G1 fragment (Phe335-Val-Asp-Ile-Pro-Glu-Asn341). A quantitative radioimmunoassay, with a limit of detection of about 80 pM, was developed using this antiserum. This antiserum requires the free carboxyl group of the C-terminal asparagine for optimal recognition. If the C-terminal asparagine is excised from the sequence, replaced with closely related amino acids, or extended across the matrix metalloproteinase cleavage site, there is a 40-10,000-fold loss in detection. Using peptides cleaved from the N-terminus, it was determined that the antiserum requires the entire Phe-Val-Asp-Ile-Pro-Glu-Asn sequence for optimal recognition. The radioimmunoassay detects matrix metalloproteinase-generated G1 fragments with similar sensitivity to the Phe-Val-Asp-Ile-Pro-Glu-Asn peptide, but it does not recognize intact aggrecan. Immunoreactive aggrecan G1 fragments of molecular mass 50 kDa are generated by the matrix metalloproteinases stromelysin and gelatinase A. In contrast, under identical conditions, the closely related metalloproteinases, gelatinase B and collagenase, as well as cathepsin G, cathepsin B and human leucocyte elastase, did not generate a G1 fragment recognized by the antiserum. The anti-Phe-Val-Asp-Ile-Pro-Glu-Asn serum detects stromelysin-generated aggrecan G1 fragments from mouse, guinea pig, rabbit and human, indicating that the detection is not species-specific. This antiserum and radio-immunoassay should be useful for quantifying and characterizing matrix metalloproteinase-generated aggrecan G1 fragments in articular cartilage and synovial fluids from humans and various animal models of articular-cartilage destruction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7717983      PMCID: PMC1136769          DOI: 10.1042/bj3070245

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.

Authors:  A J Fosang; K Last; V Knäuper; P J Neame; G Murphy; T E Hardingham; H Tschesche; J A Hamilton
Journal:  Biochem J       Date:  1993-10-01       Impact factor: 3.857

2.  A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

Authors:  C G Knight; F Willenbrock; G Murphy
Journal:  FEBS Lett       Date:  1992-01-27       Impact factor: 4.124

3.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis.

Authors:  L S Lohmander; L A Hoerrner; M W Lark
Journal:  Arthritis Rheum       Date:  1993-02

4.  Monoclonal antibodies recognizing protease-generated neoepitopes from cartilage proteoglycan degradation. Application to studies of human link protein cleavage by stromelysin.

Authors:  C E Hughes; B Caterson; R J White; P J Roughley; J S Mort
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

5.  The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B.

Authors:  A J Fosang; P J Neame; K Last; T E Hardingham; G Murphy; J A Hamilton
Journal:  J Biol Chem       Date:  1992-09-25       Impact factor: 5.157

6.  Recombinant human interleukin-1 beta-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid.

Authors:  J McDonnell; L A Hoerrner; M W Lark; C Harper; T Dey; J Lobner; G Eiermann; D Kazazis; I I Singer; V L Moore
Journal:  Arthritis Rheum       Date:  1992-07

7.  Cleavage of proteoglycan aggregate by leucocyte elastase.

Authors:  M T Mok; M Z Ilic; C J Handley; H C Robinson
Journal:  Arch Biochem Biophys       Date:  1992-02-01       Impact factor: 4.013

8.  Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage.

Authors:  C R Flannery; M W Lark; J D Sandy
Journal:  J Biol Chem       Date:  1992-01-15       Impact factor: 5.157

9.  Novel antibodies specific for proteolyzed forms of protein kinase C: production of anti-peptide antibodies available for in situ analysis of intracellular limited proteolysis.

Authors:  H Kikuchi; S Imajoh-Ohmi; S Kanegasaki
Journal:  Biochim Biophys Acta       Date:  1993-03-05

10.  Hyaluronan-binding region of aggrecan from pig laryngeal cartilage. Amino acid sequence, analysis of N-linked oligosaccharides and location of the keratan sulphate.

Authors:  F P Barry; J U Gaw; C N Young; P J Neame
Journal:  Biochem J       Date:  1992-09-15       Impact factor: 3.857

View more
  15 in total

Review 1.  The use of cleavage site specific antibodies to delineate protein processing and breakdown pathways.

Authors:  J S Mort; D J Buttle
Journal:  Mol Pathol       Date:  1999-02

2.  Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury.

Authors:  M L Lemons; J D Sandy; D K Anderson; D R Howland
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

3.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

4.  Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro.

Authors:  C B Little; C R Flannery; C E Hughes; J S Mort; P J Roughley; C Dent; B Caterson
Journal:  Biochem J       Date:  1999-11-15       Impact factor: 3.857

5.  Characterization of helical cleavages in type II collagen generated by matrixins.

Authors:  M Vankemmelbeke; P M Dekeyser; A P Hollander; D J Buttle; J Demeester
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

6.  Investigating ADAMTS-mediated aggrecanolysis in mouse cartilage.

Authors:  Heather Stanton; Suzanne B Golub; Fraser M Rogerson; Karena Last; Christopher B Little; Amanda J Fosang
Journal:  Nat Protoc       Date:  2011-03-03       Impact factor: 13.491

7.  Increased vulnerability of postarthritic cartilage to a second arthritic insult: accelerated MMP activity in a flare up of arthritis.

Authors:  J B van Meurs; P L van Lent; A A van de Loo; A E Holthuysen; E K Bayne; I I Singer; W B van den Berg
Journal:  Ann Rheum Dis       Date:  1999-06       Impact factor: 19.103

8.  Development of a cleavage-site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids.

Authors:  A J Fosang; K Last; P Gardiner; D C Jackson; L Brown
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

9.  Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope.

Authors:  J S Mort; M C Magny; E R Lee
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

10.  VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.

Authors:  I I Singer; D W Kawka; E K Bayne; S A Donatelli; J R Weidner; H R Williams; J M Ayala; R A Mumford; M W Lark; T T Glant
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.